Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO

Regeneron Pharmaceuticals, Inc. is set to present the latest clinical data from its oncology pipeline at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain. The presentations will highlight the potential of Regeneron’s investigational drug, Libtayo® (cemiplimab), as both a monotherapy and in combination with other treatments for various solid tumors.

One of the key presentations will feature the Phase 2 trial data of Libtayo in neoadjuvant cutaneous squamous cell carcinoma (CSCC). This study will showcase the first-ever survival data for neoadjuvant Libtayo therapy in CSCC, including event-free survival outcomes. The primary analysis of this trial was shared at last year’s ESMO meeting, and the new data will provide further insights into the potential benefits of Libtayo in treating this type of cancer.

In addition, Regeneron will present the Phase 1 dose-escalation results for the investigational combination of Libtayo and ubamatamab in patients with recurrent ovarian cancer. Ubamatamab is an investigational bispecific antibody designed to activate T cells and target cancer cells. The early results from this study will shed light on the safety and efficacy of this novel combination therapy.

Furthermore, Regeneron will present subgroup analyses of Libtayo in advanced non-small cell lung cancer (NSCLC), focusing on specific patient populations such as those with squamous cell carcinoma and varying levels of PD-L1 expression. These analyses will provide valuable insights into the potential benefits of Libtayo in different subgroups of NSCLC patients.

Israel Lowy, Senior Vice President, Translational and Clinical Oncology at Regeneron, expressed the company’s commitment to advancing the development of meaningful cancer therapies. He highlighted the importance of the data presentations at ESMO in demonstrating Regeneron’s deep understanding of cancer biology, genetics, and the immune system.

Regeneron’s oncology pipeline includes a range of innovative therapies, such as checkpoint inhibitors, bispecific antibodies, and costimulatory bispecific antibodies. The company’s approved PD-1 inhibitor, Libtayo, serves as the backbone for many of these investigational combinations.

Regeneron’s progress in the field of oncology extends beyond ESMO, with recent achievements including FDA Fast Track Designation for the combination of fianlimab (LAG-3) and Libtayo in melanoma. The company remains dedicated to improving the lives of cancer patients and looks forward to sharing more groundbreaking research with the global oncology community.

Regeneron’s commitment to cancer care is driven by its scientific innovation, extensive clinical programs, and collaborations with patients, healthcare providers, governments, and biopharma companies. With a focus on difficult-to-treat cancers, Regeneron aims to transform the landscape of cancer care through its cutting-edge technologies and therapeutic approaches.

Libtayo, Regeneron’s fully human monoclonal antibody targeting the immune checkpoint receptor PD-1, has shown promising results in various advanced cancers. It has received approvals for the treatment of advanced basal cell carcinoma, advanced cutaneous squamous cell carcinoma, advanced non-small cell lung cancer, and advanced cervical cancer in different regions.

Regeneron’s VelocImmune® technology, which utilizes genetically humanized mice to produce optimized fully human antibodies, has been instrumental in the development of several FDA-approved or authorized monoclonal antibodies, including Libtayo. This technology, along with Regeneron’s other proprietary platforms, enables the company to accelerate and improve the drug development process.

As Regeneron continues to advance its oncology pipeline and collaborate with various stakeholders, it remains dedicated to its mission of transforming cancer care and improving the lives of patients affected by this devastating disease.

Leave a comment